Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX)
jumped 6.4% in the morning session after the company reported strong second-quarter financial results that beat Wall Street expectations and raised its full-year guidance.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) announced better-than-expected revenue in Q2 CY2025, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.62 per share was 1.9% above analysts’ consensus estimates.
QUEST DIAGNOSTICS INC (NYSE:DGX) offers a reliable dividend with steady growth, strong profitability, and sound financial health, making it a compelling choice for income investors.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
QUEST DIAGNOSTICS INC (NYSE:DGX) offers a reliable dividend with strong profitability and financial health, making it a solid pick for income investors.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics services industry, including Quest (NYSE:DGX) and its peers.
